[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Biotech_Beast "Some pretty brutal language in the $REPL CRL press release today. "The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.""
@Biotech_Beast on X 2025-07-22 11:21:54 UTC 1718 followers, 1009 engagements

"If $REPL gets a CRL tomorrow the whole sector could tank as it would confirm a tougher FDA or at least CBER And if it is approved could clear up a whole lot of FDA uncertainty the sector is facing. Hope it is the latter. $XBI"
@Biotech_Beast on X 2025-07-21 16:30:38 UTC 1718 followers, 12.4K engagements

"$ALT has recovered slightly the past month since data from the IMPACT trial of pemvidutide in MASH produce mixed results at XX weeks. The fibrosis improvement isn't on par with $ETNB and $AKRO although pemvidutide has other advantages"
@Biotech_Beast on X 2025-07-24 15:28:10 UTC 1718 followers, XXX engagements

"There is still a 48-week update coming for $ALT and business development is always a possibility. Still the company missed one of its best chances to display the value of pemvidutide in a more resounding fashion"
@Biotech_Beast on X 2025-07-24 15:29:44 UTC 1718 followers, XXX engagements